US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Amferia Reaches Milestone of 33 Granted Patents Across 20 Jurisdictions, Positioning the Company for Growth in the Antimicrobial Wound Care Market

From a single novel hydrogel patent filed in 2017 to a portfolio of 50 applications worldwide, Amferia’s IP strategy mirrors the depth and rigor of the science that earned the company an FDA DeNovo Classification—and signals a company built to compete at scale.GOTHENBURG, SWEDEN—Amferia, a Swedish medtech scale-up pioneering next-generation antimicrobial wound care, today announced it has reached 33 granted patents across 20 jurisdictions globally, with a total portfolio of 50 patent applications representing four distinct technology families. The milestone reflects Amferia’s disciplined

Amferia Annual General Meeting (AGM) Appoints Global Healthcare Leaders Randy Schwartz and Nikolaj Sørensen to Board of Directors

Amferia AB is pleased to announce the appointment of two new board members, Randy Schwartz and Nikolaj Sørensen, to help guide the company's next phase of global expansion. Following Amferia’s recent FDA De Novo classification, the company is actively preparing to accelerate its commercial entry into the US market. The addition of these two accomplished leaders brings targeted expertise in wound care commercialization, advanced medical devices, and international life science strategy—providing a powerful foundation for Amferia's continued growth.Mölndal, Sweden—Following the FDA's grant of

Following the U.S. FDA De Novo Classification, Amferia Seeks Potential Partners to Market the World’s First Antibacterial Peptide-Based Wound Dressing

With the FDA De Novo Classification granted, Swedish medtech firm Amferia now seeks partners to bring the first-ever wound care product featuring antibacterial peptides as the mechanism for fighting infection to the U.S. market. The decision creates a new regulatory category for wound dressings in the U.S.GOTHENBURG, SWEDEN—Following approval by the U.S. Food and Drug Administration (FDA) for its antibacterial wound dressing, Amferia representatives will attend the European Wound Management (EWMA) Congress in Bremen, Germany, May 6-8, 2026, to discuss expansion of its products into the U.S.

Amferia Signs Major Animal Health Distribution Contract with Interchem (Ireland) Ltd, Expanding into Ireland

Amferia, a Swedish medtech company developing next-generation peptide-based wound care, today announced a strategic distribution partnership with Interchem (Ireland) Ltd, a premier animal health company in Ireland. This collaboration aims to make Amferia’s innovative wound dressings available to Irish veterinary professionals as early as Spring 2026.The introduction of the AMP Wound Dressing addresses a critical need for advanced wound management and bioburden reduction in both small and large animals. This launch is particularly timely given the escalating global concerns regarding

FDA Grants De Novo Classification Request to Market the World’s First Antibacterial Peptide-Based Wound Dressing

In granting the De Novo Classification Request, FDA allows Swedish medtech firm Amferia to market the first-ever wound care product featuring antibacterial peptides as the mechanism for fighting infection. The decision creates a new regulatory category for wound dressings in the U.S.GOTHENBURG, SWEDEN—Amferia today announced that its antibacterial wound dressing has been granted approval by the U.S. Food and Drug Administration (FDA) through the De Novo Classification Request track, allowing Amferia to enter the U.S. market with a unique Class 2 medical device antibacterial dressing for

Amferia signs major contract in Animal Health with Grovet BV and Expands into the Benelux markets

Mölndal, Sweden — February 5, 2026 — An innovative new wound care technology will now allow veterinarians in the Benelux countries to protect wounds from bacterial infections and help heal animal wounds faster. Amferia, a Swedish medtech company developing next-generation antimicrobial wound-care solutions, announced a distribution partnership with Grovet BV —a major player serving the animal health market in European countries including Netherlands, Belgium, and Luxemburg.The joint efforts will aim to make products available as soon as the spring of 2026.   The partnership with

Medtech Firm Amferia signs major contract in Animal Health with Magnum Veterinaaria and Expands into the Baltic States

Mölndal, Sweden — January 27, 2026 — An innovative new wound care technology will now allow veterinarians in the Baltic countries to protect wounds from bacterial infections and heal animal wounds faster. Amferia, a Swedish medtech company developing next-generation antimicrobial wound-care solutions, announced a distribution partnership with Magnum Veterinaaria—a major player serving the animal health market in Baltic States of Latvia, Lithuania, and Estonia.The joint efforts will aim to make products available as soon as the spring of 2026.   The partnership with Magnum will bring a

Medtech Firm Amferia Secures €3.5M Investment to Accelerate Breakthrough Antimicrobial Technology in Human and Animal Health

Mölndal, Sweden — December 15, 2025 — Amferia, a Swedish medtech company developing next-generation antimicrobial wound-care solutions, today announced the close of an oversubscribed €3.5 million investment round.   The new funding—led by both existing shareholders and several new investors prominent in global wound care—will accelerate clinical development in human health, scale Amferia’s growing animal-health business, and support commercialization of new products based on its proprietary antimicrobial peptide (AMP) hydrogel platform.   This investment follows a milestone year

Amferia Technology: Breakthrough Antimicrobial Solution for Animal Wound Care

Amferia has invented a new antimicrobial hydrogel wound dressing using a peptide technology, that targets, binds, and rapidly disrupts bacteria upon contact. The hydrogel dressing does not release anything into the wound and is safe for the body.Amferia’s antimicrobial technology has been developed to address the growing need for effective wound care and bacterial reduction in wounds of both small and large animals, especially in the light of increasing concerns over antibiotic-resistant infections.   “The science behind Amferia’s technology offers the potential to reduce systemic

Therese Rydell Joins Amferia as Director of Quality and Regulatory Affairs

Amferia AB is happy to welcome Therese Rydell as the Director of Quality and Regulatory Affairs. Therese has extensive background from quality and regulatory operations in med-tech industry bringing knowledge and experience for the continued growth of Amferia. The company is now  expanding the animal health business to new markets and pursuing regulatory approval in the US.Therese has a solid background in QA/RA from global companies in the Medtech field spanning over 10 years in leading roles such as; Global QA Engineer at Mölnlycke HealthCare, Quality and Regulatory Manager at Integration

New Study finds innovative Peptide-Hydrogel restores the effectiveness of antibiotics against drug-resistant bacteria

Swedish med-tech firm Amferia announced findings that antibiotic-resistant bacteria can regain its sensitivity to antibiotics when combined with the company’s peptide-hydrogel. Results of a collaboration between Chalmers University of Technology and Amferia show that antibiotics can have a 64 times higher bactericidal effect when used together with Amferia’s proprietary material, whose antibacterial properties are also greatly enhanced by this combination. The bacteria-killing material is a proprietary hydrogel, which can be adapted to many medical applications. Photo: Saba

Amferia Recognized on Ny Teknik’s Prestigious “33-listan” for Second Consecutive Year

The significance of being on the list a second time highlights Amferia's continued growth and increasing market potential. It suggests that the company has not only managed to sustain its initial success but has also demonstrated the ability to expand and strengthen its position within the industry. Being recognized again reflects a track record of strong performance, innovation, or strategic decisions that make Amferia a promising company for future growth.Amferia has once again earned a spot on Ny Teknik’s esteemed “33-listan,” an annual list of 33 promising young Swedish companies with

Amferia wins Red Dot Award for Innovative Design addressing bacterial infections and antibiotic resistance

Swedish medtech company Amferia has been awarded the Red Dot Award for its elevator pitch logotype in the Brand & Communication Design category. The new logo describes the company’s innovation and purpose in three words: Amferia kills bacteria.”The award highlights our commitment to addressing bacterial infections and antibiotic resistance. Amferia’s innovation contributes to the solution, but we also have to communicate that in an innovative way to reach a global audience.” says Anand Rajasekharan, CEO and co-founder of Amferia.   The Red Dot Award, established in 1955,

First Product Utilizing Amferia Antimicrobial Technology Launched in Europe for Animal Wound Care

The Snögg BactiDefend Dressing, a new product in animal wound care using Amferia’s proprietary antimicrobial technology, has been launched for professional veterinary use across several European countries. The introduction of BactiDefend is the result of a partnership between Amferia and Orkla Wound Care, released under Orkla’s Snögg Animal Care brand. This collaboration aims to address the growing need for effective wound care and bacterial reduction in wounds of both small and large animals, especially in the light of increasing concerns over antibiotic-resistant infections.

Amferia closes €1,2 million investment to combat resistant bacterial infections

Swedish medtech company Amferia announces the successful completion of its latest investment round, boosting its mission to combat wound infections. During 2024, Amferia has signed important commercial agreements with leading animal health companies in Europe for commercialization of the company’s proprietary technology — a wound dressing for animals that also kills resistant bacteria.Mölndal, Sweden (September 3rd, 2024): Amferia, a Swedish medtech company focused on developing innovative antimicrobial healthcare solutions, announces the successful closure of a 1.2-million-euro investment

Amferia signs major animal health contract with Biokema and expands into Switzerland

Swedish medtech company Amferia, with a mission to combat infections globally, announces the signing of its second commercial agreement. The contract is with the leading Swiss animal health company Biokema SA for commercialization of Amferia’s proprietary wound care technology for Animal Health in Switzerland — a wound dressing for animals that kills bacteria even resistant bacteria.[A close-up of a logo Description automatically generated] Anand Rajasekharan, CEO of Amferia — “Biokema’s market leadership in animal health will spearhead Amferia’s vision of reducing antibiotic resistant

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe

Media